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Rectum 0.34 0.48 0.46 0.37 -0.06 -0.06 -0.06 -0.04 
Sigmoid 1.39 0.96 0.72 0.66 0.44 0.22 0.18 0.17 
Anus 0.81 0.99 0.54 0.68 -0.07 -0.13 -0.09 -0.09 
Femoral 
heads 1.66 1.49 1.45 1.47 -0.44 -0.4 -0.41 0.43 
Penile bulb 0.43 0.33 0.27 0.39 -0.02 -0.04 -0.03 -0.11 
 
A SD of 0.5-1 cm was measured for the anus with the largest 
discrepancies for its proximal part. A good correlation between 
delineations was observed for the rectum with a SD of 0.3-0.5 cm with 
the largest discrepancy for its distal part. The sigmoid had a SD of 0.6-
1.4 cm between observers with the largest discrepanties for its distal 
part. A SD of 1.4-1.7 cm was observed between delineation of the 
femoral heads with largest discrepanties for their distal parts. A small 
SD of 0.3-0.4 cm was obtained for the penile bulb. 
Conclusions: Given SD < 0.5 cm for the rectum and penile bulb, the 
suggested guidelines were easy to follow and found sufficient in 
delineation of these OARs. Larger SD in delineation of the anus, 
sigmoid and femoral heads appeared to result from incomplete 
guidelines for those OARs. Stricter guidelines with better definition of 
OAR anatomical borders-particuly the proximal borders of the anus 
and distal borders of sigmoid and femoral heads- are needed.  
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Purpose/Objective: New treatments are being introduced in the 
treatment of locally advanced esophageal cancer. Some, such as 
trastuzumab, can potentially increase cardiotoxicity. The purpose of 
this study was to model cardiac toxicity using an empirical normal 
tissue complication probability (NTCP) model in patients with 
esophageal cancer treated in part with radiotherapy. 
Materials and Methods: Cardiactoxicity as measured by Common 
Toxicity Criteria Adverse Events (CTCAE) v3.0 and Radiation Therapy 
Oncology Group (RTOG) toxicity grading scale was identified by 
retrospective chart review. The probability of cardiac toxicity as a 
function of absorbed dose in a partial volume was modeled by the 
method of Lyman, by converting the dose volume histograms into an 
equivalent fractional volume receiving the maximum dose in the DVH, 
using the effective volume method of Kutcher and Burman. The 
parameters in this model (D50, slope mand volume exponent n) were 
determined by maximum likelihood estimation. Doses prescribed in 
fractional doses other than 1.8 Gy were converted to equivalent dose 
in 1.8 Gy fractions assuming an α/β ratio of 1.4 Gy, determined from 
this data set by intercomparing combinations of total dose and dose 
per fraction giving similar levels of toxicity. 
Results: From 6/02 to 4/12, 150 patients (113 male and 37 female) 
with locally advanced esophageal cancer undergoing pre-operative or 
definitive CRT at 2 NCI Comprehensive Cancer Centers form the basis 
of this analysis. The mean radiotherapy dose was 4912 (range:3000-
5940) cGy. Chemotherapy was at the discretion of the treating 
medical oncologist. Thirty-four (23%) developed a cardiac toxicity 
with 10 being symptomatic (> grade 3 toxicity). The mean time to any 
toxicity was 8 (range:1-29) months. Cardiac toxicity types were 
Pericardial effusion-27; Heart failure- 2, Atrial Fibrillation-1, 
Cardiomegaly-1, Ischemia-1, MI-1, Sick sinus syndrome-1. The 
maximum likelihood fit of the Lyman model parameters to patients 
with cardiac symptoms were n = 0.4 m= 0.34, TD50=54.2 Gy for men 
and TD50=41.8 Gy for women, p=0.027.  
Conclusions: These results are comparable to earlier reports. What is 
not known, however, is the use of a single toxicity endpoint rather 
than combined endpoints. The pathophysiologic etiology of pericardial 
effusion most likely is not the same as heart failure, one being an 
effect on the pericardium while the other an effect on the cardiac 
myocytes. Further work is needed to clarify the dose resulting in 
toxicity to each cardiac structure necessary to result in cardiactoxicity 
and why we see a difference between men and women.  
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Purpose/Objective: Several studies have shown that breast cancer 
treatment may increase the risk of cardiovascular disease after ten or 
more years. However, most reports are based on older treatment 
regimens. It is not known whether more contemporary radiation 
techniques are associated with excess cardiovascular disease. In 
addition, it is not clear whether current chemotherapeutic regimens, 
especially regimens containing anthracyclines, increase the risk of 
cardiovascular disease in breast cancer survivors. 
The aim of this study is to assess the effect of radiotherapy and 
chemotherapy for breast cancer on cardiovascular morbidity and 
mortality. 
Materials and Methods: We have constructed a large population-
based cohort of patients diagnosed with invasive breast cancer 
between 1989 and 2004 (n=93,630). Information on patient 
characteristics, primary and secondary malignancies, and basic 
treatment information (e.g. type of surgery, radiotherapy yes/no, 
chemotherapy yes/no) were provided by the Netherlands Cancer 
Registry. Detailed treatment information was collected through 
electronic files from radiotherapy institutes, trials, and regional 
studies. Date and cause of death were acquired through linkage with 
the Central Bureau for Genealogy and Statistics Netherlands, 
respectively, until January 2010. Data on cardiovascular morbidity 
were acquired through linkage with two registries: the Hospital 
Discharge Registry (LMR) and the Cardiac Interventions Registry (BHN). 
Results: Of the initial 93,630 patients, 69,123 survived at least five 
years after breast cancer diagnosis. The median follow-up of five-year 
survivors was 9.7 years (range 5-21 years).  
We distinguished four mutually exclusive treatment categories: 
surgery only (33%), radiotherapy with or without surgery (46%), 
radiotherapy and chemotherapy with or without surgery (15%), and 
chemotherapy with or without surgery (6%). 52% of the patients 
treated with radiotherapy were irradiated for left-sided breast 
cancer. Due to the anatomical position of the heart, the radiation-
dose to the heart is higher during left-sided radiotherapy than during 
right-sided radiotherapy. 
At the PREVENT meeting, results will be presented on the evaluation 
of mortality rates in comparison with the general population. 
Secondly, we will present comparisons of cardiovascular mortality 
rates and incidence of different cardiovascular diseases between the 
above stated treatment categories, and more specifically by type of 
chemotherapeutic, radiation field, and laterality. 
Conclusions: Based on our results, conclusions will be drawn with 
respect to the effects of modern radiotherapy regimens and specific 
chemotherapeutics for breast cancer.  
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Purpose/Objective: Radiation-induced heart disease (RIHD) is a long-
term side effect of radiotherapy of intrathoracic and chest wall 
tumors when radiation fields encompass all or part of the heart. 
Tocotrienols are forms of vitamin E with potent radioprotective 
properties. This study investigates the effects of pre-treatment and 
